Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) has earned a consensus recommendation of “Hold” from the five research firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $8.18.
Several research firms recently commented on RXRX. Morgan Stanley set a $5.90 price target on shares of Recursion Pharmaceuticals in a research report on Friday, October 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, October 15th. Wall Street Zen upgraded shares of Recursion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $8.00 target price on shares of Recursion Pharmaceuticals in a report on Monday, October 19th.
Check Out Our Latest Research Report on RXRX
Recursion Pharmaceuticals Stock Up 0.6%
Shares of NASDAQ RXRX traded up $0.02 during mid-day trading on Friday, reaching $3.52. The company had a trading volume of 15,546,436 shares, compared to its average volume of 29,299,366. The firm has a 50 day simple moving average of $3.77 and a two-hundred day simple moving average of $3.52. Recursion Pharmaceuticals has a 52-week low of $2.77 and a 52-week high of $5.24. The company has a current ratio of 5.03, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. The stock has a market cap of $1.88 billion, a P/E ratio of -3.91 and a beta of 1.15.
Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) last released its quarterly earnings results on Monday, November 2nd. The company reported ($0.22) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.22). The firm had revenue of $18.55 million for the quarter, compared to the consensus estimate of $14.81 million. Recursion Pharmaceuticals had a negative return on equity of 46.47% and a negative net margin of 697.15%. During the same quarter last year, the business posted ($0.36) EPS. Sell-side analysts predict that Recursion Pharmaceuticals will post -0.89 earnings per share for the current year.
Insider Buying and Selling at Recursion Pharmaceuticals
In other Recursion Pharmaceuticals news, CEO Najat Khan sold 22,408 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, September 8th. The stock was sold at an average price of $3.52, for a total value of $78,876.16. Following the transaction, the chief executive officer directly owned 2,072,890 shares in the company, valued at approximately $7,296,572.80. This trade represents a 1.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 25,000 shares of the stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $5.00, for a total value of $125,000.00. Following the sale, the director directly owned 162,156 shares of the company’s stock, valued at approximately $810,780. This represents a 13.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 167,408 shares of company stock valued at $701,276 in the last ninety days. Insiders own 6.65% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $7,370,000. Hsbc Holdings PLC boosted its stake in shares of Recursion Pharmaceuticals by 537.3% in the fourth quarter. Hsbc Holdings PLC now owns 818,316 shares of the company’s stock valued at $3,367,000 after buying an additional 689,903 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Recursion Pharmaceuticals by 18.2% in the first quarter. Bank of America Corp DE now owns 2,496,831 shares of the company’s stock valued at $7,665,000 after buying an additional 384,486 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Recursion Pharmaceuticals by 29.3% in the first quarter. Bank of New York Mellon Corp now owns 1,462,631 shares of the company’s stock valued at $4,490,000 after buying an additional 331,048 shares in the last quarter. Finally, First Trust Advisors LP grew its holdings in Recursion Pharmaceuticals by 15.2% during the first quarter. First Trust Advisors LP now owns 2,610,726 shares of the company’s stock worth $8,015,000 after acquiring an additional 344,035 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.
Recursion Pharmaceuticals Company Profile
Recursion Pharmaceuticals, Inc is a biotechnology company that uses advanced computing, artificial intelligence and automated biology to discover and develop new medicines. The company’s platform, known as the Recursion Operating System, combines large-scale biological experimentation with machine learning and data analysis to identify potential drug candidates and characterize how diseases respond to treatments.
Recursion applies its technology to a range of therapeutic areas, including oncology, rare diseases, neuroscience and infectious diseases.
Featured Articles
- Five stocks we like better than Recursion Pharmaceuticals
- Astera Labs Just Crushed Earnings—So Why Are Analysts Cutting Price Targets?
- Sandisk Shares Are Oversold: Bargain or Value Trap?
- IonQ’s Record Revenue Includes a Big SkyWater Boost: Does That Change the Story?
- Airbnb Defied a Brutal Tech Sell-Off, But Can Its Post-Earnings Rally Last?
Receive News & Ratings for Recursion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recursion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
